96,910 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA bought a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 96,910 shares of the company’s stock, valued at approximately $3,849,000. Pictet Asset Management Holding SA owned approximately 0.06% of Centessa Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $36,000. T. Rowe Price Investment Management Inc. increased its position in shares of Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $100,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Wolfe Research cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $35.00 to $42.00 in a report on Monday, April 20th. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $40.50 on Friday. The company has a market capitalization of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The company has a 50-day simple moving average of $39.85 and a 200 day simple moving average of $32.08. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.74 and a 52 week high of $40.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.